Gains of 2p involving the REL locus correlate with nuclear c-Rel protein accumulation in neoplastic cells of classical Hodgkin lymphoma

Blood

Volumn 101, Issue 9, 2003, Pages 3681-3686

  Barth, Thomas F E ^c   Martin Subero, José I ^c   Joos, Stefan ^c   Menz, Christiane K ^c   Hasel, Cornelia ^c   Mechtersheimer, Gunhild ^c   Parwaresch, Reza M ^c   Lichter, Peter ^c   Siebert, Reiner ^b   Möller, Peter ^a  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TRANSCRIPTION FACTOR REL; HYBRID PROTEIN; TUMOR PROTEIN;

ARTICLE; BIOACCUMULATION; CHROMOSOME 2; CHROMOSOME TRANSLOCATION; CLINICAL ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOGENETICS; GENE LOCUS; GENE TARGETING; HODGKIN DISEASE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REED STERNBERG CELL; STRUCTURAL CHROMOSOME ABERRATION; CELL LINE; CELL NUCLEUS; CHROMOSOME ABERRATION; COMPARATIVE STUDY; CYTOLOGY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION REGULATION; GENE TRANSLOCATION; GENETIC TRANSFECTION; GENETICS; HYPERPLASIA; INTERPHASE; KIDNEY; METABOLISM; NUCLEIC ACID HYBRIDIZATION; PATHOLOGY; PHYSIOLOGY; PRENATAL DEVELOPMENT; PROTO ONCOGENE; SINGLE BLIND PROCEDURE; TONSIL; ULTRASTRUCTURE;

CELL LINE; CELL NUCLEUS; CHROMOSOME ABERRATIONS; CHROMOSOMES, HUMAN, PAIR 2; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REL; HODGKIN DISEASE; HUMANS; HYPERPLASIA; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION, FLUORESCENCE; INTERPHASE; KIDNEY; NEOPLASM PROTEINS; NF-KAPPA B; NUCLEIC ACID HYBRIDIZATION; PROTO-ONCOGENE PROTEINS C-REL; RECOMBINANT FUSION PROTEINS; REED-STERNBERG CELLS; SINGLE-BLIND METHOD; TONSIL; TRANSFECTION; TRANSLOCATION, GENETIC;

EID: 0037866407     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-08-2577     Document Type: Article

References (42)

1. Küppers R, Schwering I, Bräuninger A, Rajewsky K, Hansmann ML. Biology of Hodgkin's lymphoma. Ann Oncol. 2002;13(suppl 1):11-18.
2. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and Reed-Sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000;95:1443-1450.
3. Staudt LM. The molecular and cellular origins of Hodgkin's disease. J Exp Med. 2000;191:207-212.
4. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood. 2002;99:4283-4297.
5. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin's disease tumor cells. J Clin Invest. 1997;100:2961-2969.
6. Hinz M, Loser P, Mathas S, Krappmann D, Dörken B, Scheidereit C. Constitutive NF-κB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood. 2001;97:2798-2807.
7. Joos S, Küpper M, Ohl S, et al. Genomic imbalances including amplification of the tyrosine kinase gene JAK2 in CD30+ Hodgkin cells. Cancer Res. 2000;60:549-552.
8. Joos S, Menz CK, Wrobel G, et al. Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short arm of chromosome 2. Blood. 2002;99:1381-1387.
9. Martin-Subero JI, Gesk S, Harder L, et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood. 2002;99:1474-1477.
10. Baldwin AS Jr. The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol. 1996;14:649-683.
11. Gilmore TD. The Rel/NF-kappaB signal transduction pathway: introduction. Oncogene. 1999;18:6842-6844.
12. Rayet B, Gelinas C. Aberrant rel/nfkb genes and activity in human cancer. Oncogene. 1999;18:6938-6947.
13. Siebenlist U, Franzoso G, Brown K. Structure, regulation and function of NF-kappa B. Annu Rev Cell Biol. 1994;10:405-455.
14. Wulczyn FG, Krappmann D, Scheidereit C. The NF-kappa B/Rel and I kappa B gene families: mediators of immune response and inflammation. J Mol Med. 1996;74:749-769.
15. Cabannes E, Khan G, Aillet F, Jarrett RF, Hay RT. Mutations in the IkBa gene in Hodgkin's disease suggest a tumour suppressor role for IkappaBalpha. Oncogene. 1999;18:3063-3070.
16. Jungnickel B, Staratschek-Jox A, Bräuninger A, et al. Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med. 2000;191:395-402.
17. Wood KM, Roff M, Hay RT. Defective IkappaBalpha in Hodgkin cell lines with constitutively active NF-kappaB. Oncogene. 1998;16:2131-2139.
18. Jaffe ES, Harris NL, Stein H, Vardiman JW. Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France; IARC Press; 2001.
19. Whiteside ST, Epinat JC, Rice NR, Israel A. I kappa B epsilon, a novel member of the I kappa B family, controls RelA and cRel NF-kappa B activity. EMBO J. 1997;16:1413-1426.
20. Rice NR, MacKichan ML, Israel A. The precursor of NF-kappa B p50 has I kappa B-like functions. Cell. 1992;71:243-253.
21. Latimer M, Ernst MK, Dunn LL, Drutskaya M, Rice NR. The N-terminal domain of IkappaB alpha masks the nuclear localization signal(s) of p50 and c-Rel homodimers. Mol Cell Biol. 1998;18:2640-2649.
22. Satterwhite E, Sonoki T, Willis TG, et al. The BCL11 gene family: involvement of BCL11A in lymphoid malignancies. Blood. 2001;98:3413-3420.
23. Schlegelberger B, Metzge S, Harder S, Zühlke-Jenisch R, Zhang Y, Siebert R. Classical and molecular cytogenetics of tumor cells. In: Wegner RD, ed. Diagnostic Cytogenetics. Heidelberg, Germany: Springer-Verlag; 1999:151-185.
24. Martin-Subero JI, Chudoba I, Harder L, et al. Multicolor-FICTION: expanding the possibilities of combined morphologic, immunophenotypic, and genetic single cell analyses. Am J Pathol. 2002;161:413-420.
25. Schlegelberger B, Weber-Matthiesen K, Himmler A, et al. Cytogenetic findings and results of combined immunophenotyping and karyotyping in Hodgkin's disease. Leukemia. 1994;8:72-80.
26. Kalaitzidis D, Gilmore TD. Genomic organization and expression of the rearranged REL proto-oncogene in the human B-cell lymphoma cell line RC-K8. Genes Chromosomes Cancer. 2002;34:129-135.
27. Gugasyan R, Grumont R, Grossmann M, et al. Rel/NF-kappaB transcription factors: key mediators of B-cell activation. Immunol Rev. 2000;176:134-140.
28. Tumang JR, Owyang A, Andjelic S, et al. c-Rel is essential for B lymphocyte survival and cell cycle progression. Eur J Immunol. 1998;28:4299-4312.
29. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000;403:503-511.
30. Monni O, Joensuu H, Franssila K, Klefstrom J, Alitalo K, Knuutila S. BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood. 1997;90:1168-1174.
31. Schwab M. Oncogene amplification in solid tumors. Semin Cancer Biol. 1999;9:319-325.
32. Stark A, Hulka BS, Joens S, et al. HER-2/neu amplification in benign breast disease and the risk of subsequent breast cancer. J Clin Oncol. 2000;18:267-274.
33. Siebert R, Rosenwald A, Staudt LM, Morris SW. Molecular features of B-cell lymphoma. Curr Opin Oncol. 2001;13:316-324.
34. Willis TG, Dyer MJ. The role of immunoglobulin translocations in the pathogenesis of B-cell malignancies. Blood. 2000;96:808-822.
35. Barth TF, Bentz M, Leithäuser F, et al. Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract. Genes Chromosomes Cancer. 2001;31:316-325.
36. Houldsworth J, Mathew S, Rao PH, et al. REL proto-oncogene is frequently amplified in extranodal diffuse large cell lymphoma. Blood. 1996;87:25-29.
37. Bentz M, Barth TF, Brüderlein S, et al. Gain of chromosome arm 9p is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes Chromosomes Cancer. 2001;30:393-401.
38. Goff LK, Neat MJ, Crawley CR, et al. The use of real-time quantitative polymerase chain reaction and comparative genomic hybridization to identify amplification of the REL gene in follicular lymphoma. Br J Haematol. 2000;111:618-625.
39. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:1937-1947.
40. Donelly GB, Teruya-Feldstein J, Quin J, Zelenetz AD, Houldsworth J, Chaganti RS. Nuclear expression of Rel correlates with gene amplification in diffuse large B-cell lymphomas (DLBCL) [abstract]. Blood. 2001;98:302.
41. Mathas S, Hinz M, Anagnostopoulos I, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappaB. EMBO J. 2002;21:4104-4113.
42. Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood. 2002;99:618-626.